Frozen Gloves, Socks Reduce CIPN in Patients With Breast Cancer Frozen Gloves, Socks Reduce CIPN in Patients With Breast Cancer

Cryotherapy delivered to the hands and feet during weekly paclitaxel chemotherapy significantly reduces the incidence of peripheral neuropathy in patients with breast cancer.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Related Links:

ConclusionThe addition ofweekly carboplatin to neoadjuvant paclitaxel and dd EC leads to a pCR rate comparable to prior studies (54%). However, hematological toxicity and febrile neutropenia rate was unexpectedly high. Future investigations could focus on reversing the sequence, which may lead to better hematological tolerability.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Karin Meissner1,2*, Nicola Talsky1, Elisabeth Olliges1,2, Carmen Jacob1,3,4, Oliver J. Stötzer5, Christoph Salat5, Michael Braun6 and Raluca Flondor1 1Institute of Medical Psychology, Faculty of Medicine, LMU Munich, Munich, Germany 2Division of Health Promotion, Coburg University of Applied Sciences, Coburg, Germany 3Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom 4Wessex Neurological Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom 5Haematology and Oncology, Outpatient Cancer Ca...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
This study not only provides biological evidence to support the use of duloxetine as the first standard CIPN drug but will also lead to potential new targets for CIPN drug development. Introduction A major dose-limiting complication of chemotherapy is chemotherapy-induced peripheral neuropathy (CIPN). The greatest contributors to CIPN are taxanes (e.g., paclitaxel) and platinum-based (e.g., oxaliplatin) treatments (Krukowski et al., 2015). Paclitaxel (PTX) can effectively treat several of the most common cancers including breast cancer, lung cancer, and ovarian cancer (Ewertz et al., 2015; Cetinkaya-Fisgin et al., ...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
CONCLUSION: With longer follow-up, adjuvant paclitaxel and trastuzumab is associated with excellent long-term outcomes. Distribution of PAM50 intrinsic subtypes in small HER2-positive tumors is similar to that previously reported for larger tumors. PMID: 30939096 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Oncol Source Type: research
Taxol is a common chemotherapy (CTX) drug that is associated with the development of neuropathy. Paclitaxel-induced peripheral neuropathy (PIPN) is the dose limiting toxicity of this CTX drug. Paclitaxel exerts its therapeutic effect by binding to β-tubulin, which interferes with microtubule dynamics and results in microtubule stabilization, mitotic arrest, and apoptosis of cancer cells. However, microtubules are critical for axonal function and for the transport of essential organelles to distal nerve endings.
Source: The Journal of Pain - Category: Materials Science Authors: Source Type: research
Foods like citrus and grains may affect severity of peripheral neuropathy symptoms during taxane therapy for breast cancer.Breast Cancer Research
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Conclusions ETP therapy showed acceptable efficacy and safety and is a potential first-line therapy for patients with HER2-positive MBC.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
CONCLUSIONS: Preliminary findings from PERUSE suggest that the safety and efficacy of first-line pertuzumab, trastuzumab and taxane for HER2-positive LR/MBC are consistent with results from CLEOPATRA. Paclitaxel appears to be a valid alternative taxane backbone to docetaxel, offering similar PFS and ORR with a predictable safety profile. PMID: 30796821 [PubMed - as supplied by publisher]
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Ann Oncol Source Type: research
Conclusion: Estimating the burden of chronic toxicities should contribute to enhance rational decision-making on treatments including chemotherapy in patients with low versus high risk of recurrence.Breast Care
Source: Breast Care - Category: Cancer & Oncology Source Type: research
This article is protected by copyright. All rights reserved. PMID: 30739312 [PubMed - as supplied by publisher]
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Clin Pharmacol Ther Source Type: research
More News: Brain | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Cryotherapy | Health | Hematology | Neurology | Peripheral Neuropathy